COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,557 Articles (22,400 medRxiv, 8,157 bioRxiv)

Most recent first Previous |  Page 822: Articles 8211-8220  | Next

Spike mutations of the SARS-CoV-2 Omicron: more likely to occur in the epitopes
Li, H., Chen, Z., Liu, X., Hu, P.
10.1101/2022.03.03.22271159 — Posted: 2022-03-06
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham, S., Toh, Z. Q., Wongprompitak, P., Jansarikit, L., Srisutthisamphan, K., Sapsutthipas, S., Jantraphakorn, Y., Mingngamsup, N., Licciardi, P., Chokephaibulkit, K.
10.1101/2022.03.03.22271601 — Posted: 2022-03-06
Testing Frequency Matters | An Evaluation of the Diagnostic Performance of a SARS-CoV-2 Rapid Antigen Test in United States Correctional Facilities
Lind, M. L., Schultes, O., Robertson, A., Houde, A. J., Cummings, D. A. T., Ko, A. I., Kennedy, B. S., Richenson, R. P.
10.1101/2022.03.03.22271803 — Posted: 2022-03-06
SARS-CoV-2 Seroprevalence among health care workers after the first and second pandemic wave
de Visscher, N., Holemans, X., Gillain, A., Kornreich, A., Lagasse, R., Piette, P., Ventura, M., Thys, F.
10.1101/2022.03.03.22271855 — Posted: 2022-03-06
Development of a COVID-19 risk-assessment model for participants at an outdoor music festival: Evaluation of the validity and control measure effectiveness
Murakami, M., Fujita, T., Li, P., Imoto, S., Yasutaka, T.
10.1101/2022.02.28.22271676 — Posted: 2022-03-06
Evaluation of the role of home rapid antigen testing to determine isolation period after infection with SARS-CoV-2
Cosimi, L., Kelly, C., Esposito, S., Seitz, S., Sher-Jan, C., Turcinovic, J., Friedman, K., Nashed, M., Souweine, J., Fitzgerald, N., Gabriel, S., Connor, J., Hung, D.
10.1101/2022.03.03.22271766 — Posted: 2022-03-06
SARS-CoV-2 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3rd mRNA Vaccine Dose
Roeder, A. J., Koehler, M. A., Svarovsky, S., Jasbi, P., Seit-Nebi, A., Gonzalez-Moa, M. J., Vanderhoof, J., Mckechnie, D., Edwards, B. A., Lake, D. F.
10.1101/2022.03.03.22270812 — Posted: 2022-03-06
Zonal Model of Aerosol Persistence in ICUs: Utilization of Time and Space-resolved Sensor Network
Glenn, K., He, J., Rochlin, R., Teng, S., Hecker, J., Novosselov, I.
10.1101/2022.03.03.22271831 — Posted: 2022-03-06
Reasons underlying the intention to vaccinate children aged 5-11 against COVID-19: A cross-sectional study of parents in Israel, November 2021
Morozov, N., Dror, A. A., Daoud, A., Eisenbach, N., Kaykov, E., Barhoum, M., Sheleg, T., Edelstein, M.
10.1101/2022.03.03.22271793 — Posted: 2022-03-06
The relationship between BMI and COVID-19: exploring misclassification and selection bias in a two-sample Mendelian randomisation study
Clayton, G. L., Goncalves Soares, A., Goulding, N., Borges, M. C. G., Holmes, M., Davey Smith, G., Tilling, K., Lawlor, D. A., Carter, A. R.
10.1101/2022.03.03.22271836 — Posted: 2022-03-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).